Daniel L. Flynn, Ph.D. is the Chief Scientific Officer of Grannus and serves on the Board of Directors. He most recently worked as the Executive Vice President, Chief Scientific Officer, and Founder of Deciphera Pharmaceuticals. Prior to founding Deciphera, Dr. Flynn held senior scientific leadership roles at several major companies, including Millennium Pharmaceuticals, where he served as Senior Director of Chemistry; Amgen Inc., as Director of Medicinal Chemistry; and the G.D. Searle Unit of Monsanto Company, where he was Director of Medicinal and Combinatorial Chemistry and a Research Fellow. Dr. Flynn is also an Adjunct Professor of Medicinal Chemistry at the University of Kansas and has served as National Chair of the American Chemical Society’s Division of Medicinal Chemistry. He earned both his B.S. in Pharmacy and Ph.D. in Medicinal Chemistry from the University of Kansas, followed by postdoctoral training in synthetic organic chemistry at Indiana University.